Compare Novartis AG (NVS) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Block Inc — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while Block Inc trades at $78.41 (market cap $47.50B). The key difference: Novartis AG is far larger — about 6.2× Block Inc's market cap, and Novartis AG pays a 3.07% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| NVS | XYZ | |
|---|---|---|
Market Cap | $295.37B | $47.50B |
Sector | Health | Technology |
52-Week High | $168.62 | $84.64 |
52-Week Low | $119.31 | $49.04 |
Enterprise Value | $336.69B | $42.41B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
XYZ trades at $77.97, down 1.28% on the day, with strong analyst support (75% buy ratings) and a $99.47 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, including Q2 EPS of $1.02 beating $0.871 estimates. Revenue reached $24.19B in 2025, though net margins remain thin at 1.43%. Recent news highlights Square's expanded credit card features and AI integration driving operational efficiency.
Outlook remains positive with raised 2026 guidance and 25% gross profit growth, though high P/E of 141.2 signals premium valuation. Key risks include competitive fintech pressure and execution on AI initiatives. Institutional buying and strong Cash App performance support upside potential toward price targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
